Tigecycline
CLINICAL USE
Antibacterial agent
DOSE IN NORMAL RENAL FUNCTION
Loading dose of 100 mg, then 50 mg twice daily
PHARMACOKINETICS
Molecular weight : 585.6 %Protein binding : 71–89 %Excreted unchanged in urine : 22 Volume of distribution (L/kg) : 7–9 half-life – normal/ESRD (hrs) : 42/Probably unchanged DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50 : Dose as in normal renal function 10 to 20 : Dose as in normal renal function <10 : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD : Not dialysed. Dose as in normal renal function HD : Not dialysed. Dose as in normal renal function HDF/high flux : Unknown dialysability. Dose as in normal renal function CAV/VVHD : Unknown dialysability. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs Anticoagulants: possibly enhanced anticoagulant effect of coumarins Oestrogens: possibly reduced contraceptive effects of oestrogens (risk probably small) ADMINISTRATION
Reconstition
5.3 mL of sodium chloride 0.9% or glucose 5% (gently swirl to reconstitute) Route
IV infusion
Rate of Administration
30–60 minutes Comments
Add required dose to 100 mL of sodium chloride 0.9% or glucose 5% OTHER INFORMATION
AUC increased by 30% in CKD 5 .
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home